In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. Keith Speights for Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Copy and paste multiple symbols separated by spaces. Invest better with The Motley Fool. But there is no question some big-name stocks performed better than others along the way. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. Theres even room for more lines. Plus500. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. The company initiated its Phase 3 trial of OCU300 back in July 2018. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. But it does mean something. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The potential synergies of such a union do not seem clear. These symbols will be available throughout the site during your session. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. The company stated that it will pursue a path to file for full FDA approval of Covaxin. That product drives the current bull case for Ocugen stock. The equity has experienced a continual decline for years. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Type a symbol or company name. Written by All rights reserved. However, even from this limited vantage point, OCGN appears destined to fail. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. How can we possibly evaluate a stock on a fundamental basis with that being reality? The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. The Motley Fool has no position in any of the stocks mentioned. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. The Motley Fool has a disclosure policy. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Ocugen isnt a promotional, fly-by-night penny stock. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Its certainly possible. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Ill be sticking to the stocks that are actually working. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. It is very important to do your own analysis before making any investment. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Source: Chart courtesy of StockCharts.com. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. First, the balance sheet is in at least decent shape. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. That's not going to happen now. *Stock Advisor returns as of November 20, 2020. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. But realizing value in practice usually is a difficult endeavor. Copyright 2023 InvestorPlace Media, LLC. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. quotes delayed at least 15 minutes, all others at least 20 minutes. The short answer is: everything. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. The latest closing stock price for Ocugen as of March 03, 2023 is. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . But just because a company does not have crippling debt doesnt mean its a buy. Investors were hopeful that the small drugmaker would be able to win U.S. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. If Ocugen goes up, you can still profit. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. Its worth emphasizing: Ocugen stock is a play with enormous risk. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. At the beginning of 2020, Ocugen shares were trading at just 47 cents. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Most biotech companies have intriguing stories on paper; Ocugen is no different. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. Copyright Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Copyright 2023 InvestorPlace Media, LLC. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Written by Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. At the time, Ocugen was left for dead. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. It brings in no revenue. Histogenics itself highlights the risks involved in small-cap biotech. Here are three prudent steps to take. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). quotes delayed at least 15 minutes, all others at least 20 minutes. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. The odds of Ocugen stock winding up at zero are material. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. See disclosure here. The Motley Fool->. The average Ocugen stock price for the last 52 weeks is 2.10. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). market." On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. Maybe OCGN stock will be one of them again. The content is intended to be used for informational purposes only. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. (See OCGN stock analysis on TipRanks). I will concede this: The one great thing about the stock market is there is a style for everyone. Our 3 Top Picks. Our 3 Top Picks. Not an offer or recommendation by Stocktwits. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations.
How To Knit Gloves With Two Needles,
Be An Audience Member In Los Angeles,
Trinidad, Colorado Breaking News,
Articles O
